DK1465912T3 - Kimære TNF-ligander - Google Patents

Kimære TNF-ligander

Info

Publication number
DK1465912T3
DK1465912T3 DK02797229T DK02797229T DK1465912T3 DK 1465912 T3 DK1465912 T3 DK 1465912T3 DK 02797229 T DK02797229 T DK 02797229T DK 02797229 T DK02797229 T DK 02797229T DK 1465912 T3 DK1465912 T3 DK 1465912T3
Authority
DK
Denmark
Prior art keywords
tnfα
cell
sequence encoding
chimeric
subdomain
Prior art date
Application number
DK02797229T
Other languages
Danish (da)
English (en)
Inventor
Charles E Prussak
Thomas J Kipps
Mark J Cantwell
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK1465912T3 publication Critical patent/DK1465912T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DK02797229T 2001-12-06 2002-12-05 Kimære TNF-ligander DK1465912T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/006,305 US7786282B2 (en) 2001-12-06 2001-12-06 Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
PCT/US2002/039245 WO2003050254A2 (fr) 2001-12-06 2002-12-05 Nouveaux ligands chimeres du tnf

Publications (1)

Publication Number Publication Date
DK1465912T3 true DK1465912T3 (da) 2009-03-16

Family

ID=21720251

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02797229T DK1465912T3 (da) 2001-12-06 2002-12-05 Kimære TNF-ligander

Country Status (17)

Country Link
US (3) US7786282B2 (fr)
EP (1) EP1465912B9 (fr)
JP (1) JP4610194B2 (fr)
CN (1) CN1316022C (fr)
AT (1) ATE414103T1 (fr)
AU (2) AU2002362205B2 (fr)
CA (1) CA2469494A1 (fr)
CY (1) CY1110473T1 (fr)
DE (1) DE60229881D1 (fr)
DK (1) DK1465912T3 (fr)
ES (1) ES2316638T3 (fr)
HK (1) HK1070077A1 (fr)
IL (2) IL162357A0 (fr)
PT (1) PT1465912E (fr)
SI (1) SI1465912T1 (fr)
TW (1) TWI275644B (fr)
WO (1) WO2003050254A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
EP2114432B1 (fr) * 2006-12-05 2014-07-30 Memgen LLC Procédés pour rendre les cancers plus sensibles aux agents chimiothérapeutiques utilisant l'isf35 chimérique
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
PL219845B1 (pl) * 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
GB201406705D0 (en) 2014-04-15 2014-05-28 Univ Liverpool Fusion proteins,polynucleotides,expression vectors, and their uses
CN107615065B (zh) 2015-03-23 2020-07-24 以埃森生物科学股份有限公司的名义经营的埃森仪器股份有限公司 对生物材料评估腺病毒或腺相关病毒的病毒类型的非缔合的病毒尺寸颗粒
US20180244750A1 (en) 2015-11-02 2018-08-30 Memgen, Llc Methods for treatment of cancer
HUP1600456A2 (en) 2016-07-19 2018-01-29 Richter Gedeon Nyrt Novel cell-based tnf-alpha binding assay
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
CA3158118A1 (fr) * 2019-11-13 2021-05-20 Julie Carson Procedes de fabrication de lymphocytes car-t
WO2022216565A1 (fr) * 2021-04-05 2022-10-13 Implicyte, Inc. Virus oncolytiques chimériques armés

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US158831A (en) * 1875-01-19 Improvement in washing-machines
US209295A (en) * 1878-10-22 Improvement in water-closets
US22017A (en) * 1858-11-09 Pen-fountain
DE3750056T2 (de) * 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
DE3879395T2 (de) 1987-05-29 1993-06-24 Sagami Chem Res Fusionsprotein, enthaltend lymphotoxin.
EP0491878B1 (fr) 1989-08-16 1997-02-19 Chiron Corporation Compositions pour l'inhibition de la formation d'hormones proteiques et emplois de celles-ci
US5519119A (en) * 1990-09-21 1996-05-21 Ishihara Sangyo Kaisha Ltd. Muteins of TNF pharmaceutical compositions and a method of making
CA2055168A1 (fr) * 1990-11-21 1992-05-22 Walter Fiers Muteines de tnf
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
AU661360B2 (en) 1991-10-25 1995-07-20 Immunex Corporation Novel cytokine
WO1993019777A1 (fr) 1992-03-30 1993-10-14 Immunex Corporation Proteines de fusion comprenant un recepteur de facteur de necrose tumorale
CZ283533B6 (cs) * 1992-04-02 1998-04-15 F. Hoffmann-La Roche Ag TNF - muteiny a způsob jejich výroby
ES2252732T3 (es) * 1992-05-26 2006-05-16 Immunex Corporation Nueva citoquina que une cd30.
AU5010793A (en) 1992-08-21 1994-03-15 Schering Corporation Human interleukin-13
WO1994004570A1 (fr) 1992-08-21 1994-03-03 Schering Corporation Ligand cd40, anticorps anti-cd40, et cd40 soluble
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5573924A (en) * 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
JP4242447B2 (ja) * 1993-01-22 2009-03-25 イミュネックス・コーポレーション Ｃｄ４０リガンド遺伝子の突然変異の検出および治療
DE69433399T2 (de) 1993-01-22 2004-10-14 Immunex Corp., Seattle Detektion und behandlung von mutationen in einem gen für einen cd40-liganden
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5861310A (en) 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
DE69433820T2 (de) 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
EP0739350B1 (fr) 1994-01-07 2008-02-27 Mochida Pharmaceutical Co., Ltd. Ligand fixant l'antigene fas
DE69534595T2 (de) * 1994-04-28 2006-05-24 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
US5606023A (en) * 1994-05-24 1997-02-25 Thomas Jefferson University Mutant tumor necrosis factor proteins
US5759536A (en) 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
CA2195665A1 (fr) 1994-07-22 1996-02-08 Robert Frederick Geoffrey Booth Compositions pharmaceutiques comprenant une proteine chimere liant le facteur de necrose tumorale
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5888764A (en) 1995-01-20 1999-03-30 Uab Research Foundation Human fas gene promoter region
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6016832A (en) * 1997-04-16 2000-01-25 Woodward Governor Company Valve for controlling gas mass flow
WO1999014325A1 (fr) 1997-09-17 1999-03-25 Mochida Pharmaceutical Co., Ltd. NOUVEAU DERIVE DU LIGAND Fas
US6451759B1 (en) 1998-01-14 2002-09-17 The Regents Of The University Of California Noncleavable Fas ligand
US7300774B1 (en) * 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
AU2001253426A1 (en) 2000-04-12 2001-10-30 University Of South Florida Regulation of systemic immune responses utilizing soluble cd40
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof

Also Published As

Publication number Publication date
WO2003050254A3 (fr) 2004-03-04
SI1465912T1 (sl) 2009-04-30
PT1465912E (pt) 2009-02-19
US20110008842A1 (en) 2011-01-13
EP1465912B9 (fr) 2009-08-12
EP1465912B1 (fr) 2008-11-12
ES2316638T3 (es) 2009-04-16
JP2005511086A (ja) 2005-04-28
US20050048476A1 (en) 2005-03-03
US7964712B2 (en) 2011-06-21
JP4610194B2 (ja) 2011-01-12
DE60229881D1 (de) 2008-12-24
CY1110473T1 (el) 2015-04-29
AU2002362205A1 (en) 2003-06-23
HK1070077A1 (en) 2005-06-10
WO2003050254A2 (fr) 2003-06-19
US20120116052A1 (en) 2012-05-10
CN1316022C (zh) 2007-05-16
TW200301777A (en) 2003-07-16
IL162357A (en) 2010-12-30
EP1465912A2 (fr) 2004-10-13
CA2469494A1 (fr) 2003-06-19
ATE414103T1 (de) 2008-11-15
EP1465912A4 (fr) 2005-04-13
AU2002362205B2 (en) 2009-12-10
TWI275644B (en) 2007-03-11
IL162357A0 (en) 2005-11-20
US7786282B2 (en) 2010-08-31
CN1612890A (zh) 2005-05-04
AU2010200912A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
HK1070077A1 (en) Chimeric tnf ligands
IL193752A0 (en) Apo-2 ligand antibodies and hybridoma cell lines which produce them
IL193886A (en) Antibodies that bind to ldcam sequences
ATE411385T1 (de) Apo-2 ligand
ATE335735T1 (de) Imidazolyl-cyclische acetale
PT770088E (pt) Nova citoquina designada lerk-5
NO990086D0 (no) Avkortete, oppl÷selige tumornekrosefaktorreseptorer av type I og type II
NO984551D0 (no) Modulatorer av TNF-receptorforbundet faktor (TRAF), deres fremstilling og anvendelse
HK1162667A1 (en) Nucleolin as marker for determining the likelihood of success of endostatin cancer therapy
TW200716746A (en) Methods for identifying a compound modulating the binding between polypeptides
WO2006039638A3 (fr) Traitement d'un hypernephrome avec un anticorps humain anti-tnf ou un fragment de cet anticorps
DK1255829T3 (da) Inhibitor af hepatocytvækstfaktoraktivator til anvendelse i modulation af angiogenese og kardiovaskularisering
ES2146243T3 (es) Inhibidores de tnf.
WO2005050198A3 (fr) Polypeptides de metadherine codant des acides nucleiques et procedes d'utilisation
WO2001062928A3 (fr) Polypeptides et acides nucleiques codant pour
WO2001070978A3 (fr) Nouveaux polypeptides et acides nucleiques codant ces polypeptides
WO2006013462A3 (fr) Facteurs de croissance nsg28, nsg30, et nsg32
WO2000024771A3 (fr) Acides nucleiques codant pour des proteines semblables a l'osteoprotegerine et methodes d'utilisation associees
WO2021016062A8 (fr) Récepteurs antigéniques chimériques contenant des domaines de liaison au glypicane 2
WO2001032874A3 (fr) Nouveaux polypeptides et acides nucleiques les codant
WO2001036644A3 (fr) Polypeptide du type cytokine regule par la proteine wnt et acides nucleiques codant ce polypeptide
WO2008140565A3 (fr) Procédé pour utiliser le récepteur 14 du facteur de nécrose tumoral
WO2001051632A3 (fr) Nouveaux polypeptides et acides nucleiques codant pour ceux-ci